Health economics of treating multidrug-resistant Gram-positive infections: a qualitative critique

teaser

This review considers analyses undertaken on the economic impact of healthcare-acquired infections and the pharmacoeconomic impact of new drug therapies, including antibiotics such as linezolid

Dilip Nathwani
MB FRCP DTM&H

Consultant Physician and Honorary Professor

Infection Unit
Ninewells Hospital and Medical School
Dundee
UK

SENTRY antimicrobial programme data for 1997